Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib (CP-690,550) in moderate to severe ulcerative colitis
NCT00787202Phase 2Completed
- Sponsor
- Pfizer
- Start
- Dec 2008
- Primary completion
- Sep 2010
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 2, randomised, double-blind trial of tofacitinib oral solution in ulcerative colitis (UC) (5 arms), sponsored by Pfizer. Primary endpoint: Percentage of Participants With Clinical Response at 8 weeks. Started Dec 2008; status: completed.
02
Drugs
tofacitinib oral solution
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT00787202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00787202.